Get the Stockscreener App
0.9798
1.60%
0.0121
Lucid Diagnostics Inc stock is traded at $0.9798, with a volume of 992.49K.
It is up +1.60% in the last 24 hours and up +3.47% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.9677
Open:
$0.9677
24h Volume:
992.49K
Relative Volume:
0.70
Market Cap:
$199.08M
Revenue:
$4.71M
Net Income/Loss:
$-58.01M
P/E Ratio:
-1.1899
EPS:
-0.8234
Net Cash Flow:
$-46.68M
1W Performance:
+2.30%
1M Performance:
+3.47%
6M Performance:
-23.78%
1Y Performance:
-3.61%
1-Day Range:
$0.96
$1.02
1-Week Range:
$0.955
$1.02
52-Week Range:
$0.8605
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.9795 | 196.68M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
110.05 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
331.95 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.59 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.51 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.72 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage - scanx.trade
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript - Benzinga
LUCD: Revenue up 17% with stable cash, first LBM coverage, and Medicare LCD decision expected soon - TradingView
Transcript : Lucid Diagnostics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Earnings call transcript: Lucid Diagnostics posts Q2 2026 revenue beat, shares slip - Investing.com
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Form 8K Lucid Diagnostics Inc For: 13 August By Investing.com - Investing.com South Africa
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision - TipRanks
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics Q2 2026 Earnings Call Transcript - MarketBeat
Lucid Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue - Quiver Quantitative
Lucid Diagnostics 2026: Revenue $1.47M, EPS ($0.08) — 10-Q Summary - TradingView
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside - Yahoo Finance
Lucid Diagnostics at canaccord growth conference: reimbursement push builds By Investing.com - Investing.com Australia
Lucid Diagnostics Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Enterprise value to EBIT forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to sales forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to book forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to earnings forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Enterprise value to EBITDA forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Enterprise value to revenue forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Lucid Diagnostics Inc (LUCD) Stock News Today - TradingKey
Lucid Diagnostics (LUCD) Projected to Announce Quarterly Earnings on Thursday - marketbeat.com
Lucid Diagnostics Secures Commercial Coverage - Moomoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
Aug 20 '25 |
Buy |
1.02 |
100,000 |
101,840 |
665,443 |
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):